Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: polysorbate 80; sodium starch glycollate type b; hypromellose; magnesium stearate; macrogol 6000; microcrystalline cellulose; colloidal anhydrous silica; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: polysorbate 80; magnesium stearate; hypromellose; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type b; macrogol 6000; lactose monohydrate - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type b; magnesium stearate; colloidal anhydrous silica; macrogol 6000; polysorbate 80; hypromellose - indicated for the treatment of hypertension.,indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30mg per 24 hours) or urinary protein in excess of 900mg per 24 hours.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; sodium starch glycollate type a; povidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan gh is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - bosentan monohydrate, quantity: 64.54 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; sodium starch glycollate type a; povidone; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red - bosentan gh is indicated for the treatment of ? idiopathic pulmonary arterial hypertension ? familial pulmonary arterial hypertension ? pulmonary arterial hypertension associated with scleroderma or ? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology,in patients with who functional class ii, iii or iv symptoms.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 20 mg (equivalent: memantine, qty 16.62 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; purified talc; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 15 mg (equivalent: memantine, qty 12.46 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; purified talc; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 10 mg (equivalent: memantine, qty 8.31 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; purified talc; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - memantine hydrochloride, quantity: 5 mg (equivalent: memantine, qty 4.15 mg) - tablet, film coated - excipient ingredients: purified talc; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology; precautions).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; povidone; crospovidone; colloidal anhydrous silica; titanium dioxide; vanillin; macrogol 8000; hypromellose; iron oxide yellow; iron oxide red - treatment of hypertension. treatment of heart failure (nyha class ii to iv) in patients receiving usual therapy (e.g. diuretics, digitalis) who are intolerant to ace inhibitors. to improve survival following myocardial infarction in clinically stable patients with clinical or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.